Companies - Fagron

Price

 
Price
-
Change
-
Change %
-
Open
-
High
-
Low
-
Volume
-

Profile

 
Profile
Fagron is specialized in the development, sale and distribution of personal care products and services intended for professionals in the health sector (doctors, pharmacists, dentists, hospitals, nursing homes, etc.).
Industry
Pharmaceutical
Description
Companies in the pharmaceutical industry develop and sell drugs. In addition, licenses on newly developed drugs are sold to other companies. Medications are strictly supervised by different supervisors. This, and the complex process of developing new drugs results in the long development time before a product makes it to the market. Companies that develop new drugs benefit from long-term protection of their products through patents. This allows them to make money on a new drug.

Key figures (2018)

 
The ratios below are calculated using the last known share price and the last known company financials.

Ratios per share

Price to Earnings
-
Price to Earnings (3 years)
-
Price to Earnings (5 years)
-
Price to earnings growth
-
Price/cashflow
-
Price/net cashflow
-
Price/book value
-
Price to sales
-

Ratios for dividend

Dividend yield
-
Pay out
20,29%

Valuation ratios

Market value/PE
-
Market value/turnover
-
Enterprise value/turnover
-0,025

Return ratios

Return on private equity
-
Return on total equity
6,22%
Profit margin
8,98%

Risk ratios

Solvability
-
Solvability
1,000
Current ratio
1,063
Debt to Equity
-

Value invest ratios

Grahams Number
€ -6,72
Grahams Value
€ -6,72
Grahams Product
-
Grahams Product (3 years)
-

2018

 

Profit and loss

Net profit (x 1 mln)
€ 42,49
Turnover (x 1 mln)
€ 473,40
Cashflow(x 1 mln)
€ 62,07
Net cashflow(x 1 mln)
€ 20,46

Balance

Private equity (x 1 mln)
-
Foreign equity (x 1 mln)
€ 682,77
Current assets (x 1 mln)
€ 199,73
Current liabilities (x 1 mln)
€ 187,81
Working capital (x 1 mln)
€ 11,92
Balance total (x 1 mln)
€ 682,77

Share

Outstanding shares (x 1 mln)
71,840
Price year-end
-
Dividend per share
€ 0,12
Earnings per share
€ 0,59
Cashflow per share
€ 0,86
Net cashflow per share
€ 0,28
Book value per share
-
Stockmarket value (x 1 mln)
-

History

 
Year
2018
2017
2016
2015
2014
Net profit (x 1 mln)
€ 42,49
€ 46,66
€ -20,56
€ -195,10
€ 16,23
Turnover (x 1 mln)
€ 473,40
€ 441,55
€ 425,05
€ 481,66
€ 450,41
Price year-end
-
€ 11,42
€ 9,71
€ 6,81
€ 6,81
Year high
-
€ 13,74
€ 10,59
€ 6,81
€ 6,81
Year low
-
€ 8,84
€ 3,79
€ 6,81
€ 6,81
Outstanding shares (x 1 mln)
71,840
71,840
53,957
31,304
31,431
Price to Earnings
-
17,575
-25,490
-1,093
13,188
Earnings per share
€ 0,59
€ 0,65
€ -0,38
€ -6,23
€ 0,52
Dividends
€ 0,12
-
-
-
€ 1,00
Dividend yield
-
-
-
-
14,68%
Pay out
20,29%
-
-
-
193,66%
Private equity (x 1 mln)
-
-
€ 152,88
€ -64,77
€ 156,95
PE per share
-
-
€ 2,83
€ -2,07
€ 4,99
Balance total (x 1 mln)
€ 682,77
€ 594,05
€ 852,84
€ 689,38
€ 973,75
Stockmarket value (x 1 mln)
-
€ 820,05
€ 524,08
€ 213,18
€ 214,05

Company analysis

 

Analysis of profit indicators

Average profit per share (7 years)
€ -0,50
Standard deviation average profit
€ 2,47 (-489,00%)
Average annual growth rate
-39,37%
Compound annual growth percentage
-6,34%
© 2009 Skuzet. All Rights Reserved.